CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
-
Keck School of Medicine of University of Southern California, Los Angeles, California, United States, 90033
UC Davis, Sacramento, California, United States, 957817
Lurie Children's; Northwestern Medicine - Northwestern Medical Group, Chicago, Illinois, United States, 60611
Texas Children's Hospital, Houston, Texas, United States, 77030
Primary Children's Hospital, Salt Lake City, Utah, United States, 84113
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
17 Years to
ALL
No
Century Therapeutics, Inc.,
2028-08